03/2024. Impact of MV140 on quality of life

European Urology Open Science publishes the results of a randomized phase III trial with MV140 (Uromune) assessing the personal impact associated with a reduction in the number of infections. 

In this study, days with infection and antibiotic consumption were assessed, as well as quality of life according to a validated questionnaire. These parameters were compared between the MV140-treated and control (placebo) groups of the clinical trial published in NEJM Evidence.

The results indicate a reduction in parameters associated with urinary tract infections and an improvement in patients’ quality of life.

MV140 is a sublingual mucosal vaccine developed by INMUNOTEK that contains the main bacteria responsible for urinary tract infections.

+ info